Lai 2006.

Study characteristics
Methods	Parallel design Analysis: analysed according to allocated treatment groups
Participants	Location China Setting: inpatients Treatment: 40 people Control: 40 people Total: mean age 60 ± 14 years, 43 men Stroke criteria: unclear stroke types, clinical diagnosis plus brain imaging (though not clear that stroke lesion had to be present), acute stroke Depression criteria: HAMD at least 7, or Zung SDS > 53, but no clear description about using which scale for inclusion criteria Other entry criteria: none stated Comparability of treatment groups: unclear Exclusion criteria: unclear
Interventions	Treatment: paroxetine 20 mg daily Control: placebo Duration: treatment continued for 2 months Duration of follow‐up (end of treatment to end of study): 0
Outcomes	Depression: HAMD, Zung SDS (abnormal if the score is > 53) Additional: Zung SAS (abnormal is the score is > 50) Death The author described that they recorded AEs but they did not report any AEs
Funding source	Source of funding not stated
Notes	−
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Placebo used, not stated if matching
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	No participant dropped out
Selective reporting (reporting bias)	High risk	No protocol, stated that they would evaluate side effects but these were not reported
Other bias	Unclear risk	Demographic details at baseline not described